Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;28(5):1171-4.
doi: 10.1038/leu.2014.16. Epub 2014 Jan 13.

WTAP is a novel oncogenic protein in acute myeloid leukemia

H Bansal  1 , Q Yihua  2 , S P Iyer  3 , S Ganapathy  1 , D A Proia, L O Penalva  4 , P J Uren  5 , U Suresh  1 , J S Carew  6 , A B Karnad  7 , S Weitman  6 , G E Tomlinson  1 , M K Rao  4 , S M Kornblau  2 , S Bansal  1
Affiliations

WTAP is a novel oncogenic protein in acute myeloid leukemia

H Bansal et al. Leukemia. 2014 May.

Erratum in

  • Leukemia. 2014 Dec;28(12):2427. Proia, D [Corrected to Proia, D A]
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Expression of WTAP in AML and effect of WTAP silencing on AML cell behavior. (a) Peripheral blood mononuclear cells from normal donors (NL) and AML patients (AML) were obtained by Ficoll–Paque density centrifugation, and protein extracts were examined for WTAP expression by western blotting. (b) Histogram of WTAP expression measured by RPPA in bulk AML cells relative to normal CD34+ cells. WTAP levels were above normal CD34+ cells in 32% of AML patients and below normal in 9%. Expression is shown in log 2 scale. The genetic and clinical information on AML patients is described in Supplementary Table 1. (c) K562 and HL-60 cells were transfected with scrambled (NS) or WTAP shRNA, and selected by puromycin. The degree of WTAP knockdown was analyzed by western blotting (inset). Stable downregulation of WTAP expression by shRNA inhibited proliferation of K562 and HL-60 cells. *P ≤ 0.05. (d) HL-60 cells stably expressing NS or WTAP shRNA were plated in methylcellulose medium, and colony formation was scored after 10 days. The values were expressed as % of colonies formed by WTAP-shRNA cells compared with NS shRNA cells taken as 100%. **P ≤ 0.01. (e) Stable K562 cells with NS or WTAP shRNA were untreated or treated with etoposide (10 µm) for 48 h. The percentage of apoptotic cells was measured by the flow cytometric annexin-V/PI staining method. **P ≤ 0.01. (f) Control (NS shRNA) or WTAP-shRNA K562 cells were subcutaneously implanted into flanks of nude mice and tumor formation and progression was monitored. Tumors originating from the control and WTAP-knockdown cells were excised and photographed. WTAP knockdown significantly reduced tumor growth in vivo. **P ≤ 0.01. (g) Ba/F3 cells were transfected with WTAP or an empty vector and G418-selected stable clones (#1 and #2) were analyzed for WTAP overexpression by western blotting (left panel). Control and stable WTAP-expressing Ba/F3 cells were grown in an IL-3-free medium for indicated time and viable cells were assessed by annexin-V/PI staining followed by FACS analysis (right panel). **P ≤ 0.01. (h) Control and stable WTAP knockdown (WTAP-KD) HL-60 cells were treated with 20 nm of PMA, and 96 h later, cells were labeled with anti-CD11b, anti-CD14 or an isotype-matched control. The expression of myeloid surface markers CD11b and CD14 was analyzed by flow cytometry. (i) WTAP knockdown inhibits the mTOR pathway. Control (NS) and stable WTAP knockdown K562 and HL-60 cell extracts were analyzed by western blot with the indicated antibodies.
Figure 2
Figure 2
Hsp90 associates with WTAP and is necessary for its stability. (a) The K562 cells were treated with vehicle (−) or Hsp90 inhibitor, ganetespib (1 µm for 6 h) followed by immunoprecipitation (IP) with IgG and WTAP antibody. The immunoprecipitates and cell lysates were immunoblotted (IB) with Hsp90, Hsp70 and WTAP antibodies. (b) The GST pull-down assay. In vitro-translated and 35S-methionine-labeled full-length WTAP was incubated with GST or GST-Hsp90 protein immobilized on glutathione–sepharose beads, and bound WTAP was detected by fluorography. Twenty percent of the in vitro-translated protein was used for pull-downs. (c) K562, MV4-11 and Kasumi-1 leukemia cells were treated with the Hsp90 inhibitor ganetespib (1 µm) for 24 h and analyzed for WTAP expression by western blotting. (d) AML blasts were isolated from peripheral blood or bone marrow of AML patients using Ficoll gradient separation followed by treatment with ganetespib (1 µm) for 24 h; WTAP expression was analyzed by western blotting. (e) MV4–11 tumor-bearing animals were given single doses of vehicle and ganetespib as described previously, and after 6 h, tumors were removed for western blot analysis using WTAP and β-actin antibody. (f) K562 cells were treated with vehicle (−) or proteasomal inhibitor (bortezomib; 100 nm) for 2 h and then treated with additional vehicle or ganetespib (1 µm) for 24 h, and cell lysates were subjected to western blot analysis using anti-WTAP and anti-β-actin antibodies. (g) K562 cells were treated as above for 6 h, and proteins extracts were immunoprecipitated (IP) with anti-WTAP followed by immunoblotting with anti-ubiquitin (top panel) and anti-WTAP (bottom panel) to detect the ubiquitinated WTAP (Ub-WTAP) and WTAP protein levels, respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–1907. - PubMed
    1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106:1154–1163. - PubMed
    1. Sugiyama H. WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40:377–387. - PubMed
    1. Little NA, Hastie ND, Davies RC. Identification of WTAP, a novel Wilms’ tumour 1-associating protein. Hum Mol Genet. 2000;9:2231–2239. - PubMed
    1. Penalva LO, Ruiz MF, Ortega A, Granadino B, Vicente L, Segarra C, et al. The Drosophila fl(2)d gene, required for female-specific splicing of Sxl and tra pre-mRNAs, encodes a novel nuclear sprotein with a HQ-rich domain. Genetics. 2000;155:129–139. - PMC - PubMed

Publication types